Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13205
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZalcberg, John Ren
dc.contributor.authorPietersz, Geoffrey Aen
dc.contributor.authorToohey, Ben
dc.contributor.authorLaird, Jen
dc.contributor.authorHuggins, Ren
dc.contributor.authorZimet, A Sen
dc.contributor.authorHennessy, O Fen
dc.contributor.authorMcKenzie, Aen
dc.contributor.authorMcKenzie, Ian F Cen
dc.date.accessioned2015-05-16T03:00:08Z
dc.date.available2015-05-16T03:00:08Z
dc.date.issued1994-05-16en
dc.identifier.citationEuropean Journal of Cancer (oxford, England : 1990); 30A(9): 1227-31en
dc.identifier.govdoc7999404en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13205en
dc.description.abstractA phase I/II study of the intralesional administration of ricin-labelled monoclonal antibodies was conducted in patients with hepatic metastases of gastrointestinal origin. The anti-carcinoembryonic antigen (CEA) antibody I-1 was conjugated to blocked ricin via a disulphide bridge. After a test dose of antibody, patients were injected with ricin-antibody conjugates under computed tomography (CT) guidance on two occasions 1 week apart. Patients with stable or responding disease would receive a third course. The dose of ricin relative to surface area was increased in a predefined manner in cohorts of 3 patients. A total of 27 patients with hepatic metastases were entered into this study. All patients had metastatic colorectal cancer (26 patients) or adenocarcinoma of unknown primary with elevated CEA levels (1 patient). The presence of malignancy was documented cytologically in 9 of 11 patients tested. Minor responses were seen in 7 patients. However, no major objective responses or changes in the growth rate of injected lesions were observed. Toxicity was generally mild, the most common being hepatic capsular pain 24-48 h after each injection. 6 patients experienced rigors. One patient had anaphylaxis. Human anti-mouse and anti-ricin antibody responses were observed. Although substantial amounts of ricin conjugated to monoclonal antibodies were delivered into single lesions, this therapeutic approach was unsuccessful. Future studies of ricin-labelled antibodies should incorporate the systemic administration of immunoconjugates.en
dc.language.isoenen
dc.subject.otherAdenocarcinoma.secondary.therapyen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAntibodies, Monoclonal.administration & dosageen
dc.subject.otherCarcinoembryonic Antigen.metabolismen
dc.subject.otherFemaleen
dc.subject.otherGastrointestinal Neoplasms.metabolism.therapyen
dc.subject.otherHumansen
dc.subject.otherImmunotoxins.administration & dosageen
dc.subject.otherInjections, Intralesionalen
dc.subject.otherLiver Neoplasms.metabolism.radiography.secondary.therapyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherRicin.administration & dosageen
dc.subject.otherTomography, X-Ray Computeden
dc.subject.otherTreatment Outcomeen
dc.titleA phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of cancer (Oxford, England : 1990)en
dc.identifier.affiliationMedical Oncology Department, Heidelberg Repatriation Hospital, Victoria, Australiaen
dc.description.pages1227-31en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/7999404en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.